SecBot SecBot
SECBOTREPLAY Home › Report › FATE

FATE · Redmile 13D/A: no change

FATE THERAPEUTICS INC · SC 13D/A filed Nov 9, 2026 at 19:08 ET

At the news

NEUTRALIMPACT 2/10

SC 13D/A filed Nov 9, 2026 at 19:08 ET

Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% due to a change in Fate Therapeutics' outstanding share count. No transactions were executed, the aggregate stake remains at 14.99% (19,164,572 shares deemed beneficially owned), and no new demands or changes in purpose were disclosed.

  • Redmile Group and related entities collectively own 19,164,572 shares of Fate Therapeutics, representing 14.99% of common stock.
  • Redmile Capital Offshore II Master Fund, Ltd. was added as a reporting person after its beneficial ownership crossed 5% due to a change in the issuer's outstanding share count.
  • No transactions were executed by the reporting persons since the prior filing (Amendment No. 10 on April 22, 2026).
  • The filing states the purpose is unchanged; no new demands, strategic review, or board representation requests were disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access